PubMed Health⌕ Search

Biomedical subjects

Johannes C van Houwelingen

Publications and source records attributed to Johannes C van Houwelingen.

3 recordsLinked to original sources

Inclusion body myositis. Clinical features and clinical course of the disease in 64 patients.

The clinical features of inclusion body myositis (IBM) were of minor importance in the design of consensus diagnostic criteria, mainly because of controversial views on the specificity of signs and symptoms, although some authors reported "typical" signs. To re-assess the clinical spectrum of IBM, a single investigator using a standard protocol studied a cohort of 64 patients cross-sectionally. Symptom onset was before the age of 50 years in 20% of cases. Only a few patients (14 %) started with weakness other than that of quadriceps, finger flexor or pharyngeal muscles. The sequence of power loss was erratic, but onset of symptoms with quadriceps weakness predicted an earlier onset of dysphagia in older patients (> or = 56 years) compared with younger ones (< 56 years) (p = 0.02). Despite widespread weakness patients had favourable scores on three commonly used function scales and they kept their employment. Complete wheel-chair dependency was rare (3 %). A dominant characteristic was the anatomical distribution of afflicted muscles: ventral extremity muscle groups were more affected than dorsal muscle groups and girdle muscles were least affected, the latter preserving postural stability. Ankylosis, especially in extension of the fingers,was frequently present. Together with the sparing of intrinsic hand muscles it was helpful in the preservation of many skillful movements. IBM has a unique distribution of muscle weakness. Ankylotic contractures are common. We feel that their joint impact on daily functioning is characteristic for the disease.

Age of Onset↗

Modeling familial clustered breast cancer using published data.

The purpose of this research was to model the familial clustering of breast cancer and to provide an accurate risk estimate for individuals from the general population, based on their family history of breast and ovarian cancer. We constructed a genetic model as an extension of a model by Claus et al. (E. B. Claus et al., Am. J. Hum. Genet., 48: 232-242, 1991), with three breast cancer genes, BRCA1, BRCA2, and a hypothetical BRCAu, in two variants, one in which BRCAu was dominant and one in which BRCAu was recessive. The model parameters were estimated using published estimates of population incidence and relative risks. Risk estimation was performed for a set of 196 counselees and for a set of simulated counselees with both the dominant BRCAu and the recessive BRCAu model, and compared relating to medical management. Estimates of the model parameters were found. Relative risks among family members were comparable between the model of Claus et al. (E. B. Claus et al., Am. J. Hum. Genet., 48: 232-242, 1991) and our model. The dominant and the recessive model provided approximately similar lifetime risks for breast cancer. Our model is suitable for breast cancer risk estimation in a health care setting.

Adult↗